Delivery Order SPE2DB20D3103-SPE2DB23FN7V3

Award Date 6/22/23
Potential Completion Date 6/23/23
Potential Value $65K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award is for the delivery of Dupixent 300 mg/2 ml pen 2 ml, a prescription medication, to the Defense Logistics Agency (DLA). The $31,884.54 contract was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, on June 11, 2024, with a completion date of June 12, 2024. The contract is a firm fixed-price delivery order with no set-aside designation, indicating open competition. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC)...
This federal contract award is for the delivery of Dupixent 300 mg/2 ml pen, a pharmaceutical product, to the Defense Logistics Agency (DLA). The $24,310.70 firm fixed-price delivery order was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, on June 21, 2024, with a completion date of June 24, 2024. The contract is not designated as a set-aside and appears to be part of a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA Troop...
This federal contract award is for the delivery of Dupixent 300 mg/2 ml pens to the Defense Logistics Agency (DLA). The $22,963.21 firm fixed-price delivery order was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has an ultimate completion date of October 25, 2024 and was awarded on October 24, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that...
This federal contract award is for the delivery of Dupixent 300 mg/2 ml pen, a specialty pharmaceutical product, to the Defense Logistics Agency (DLA). The $1,652.35 firm fixed-price delivery order was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has an ultimate completion date of June 17, 2024 and is not designated as a set-aside. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC)...
This federal contract award is for the delivery of Dupixent 300 mg/2 ml Pen 2 ml, a specialty pharmaceutical product, to the Defense Logistics Agency (DLA). The $12,457.32 firm fixed-price delivery order was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, on May 8, 2024, with a completion date of May 9, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical, which...
This federal contract award is for the delivery of Dupixent 300 mg/2 ml pen, a specialty pharmaceutical product, to the Defense Logistics Agency (DLA). The $3,304.72 firm fixed-price delivery order was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, on October 31, 2024 with a completion date of November 1, 2024. This award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, which serves as...
This federal contract award is for the delivery of Dupixent 300 mg/2 ml pens to the Defense Logistics Agency (DLA). The $4,957.08 firm fixed-price delivery order was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, on August 4, 2023. The contract has an ultimate completion date of August 7, 2023 and is not designated as a set-aside. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical through November 2026,...
This federal contract award is for the delivery of Dupixent 300 mg/2 ml pens to the Defense Logistics Agency (DLA), a defense agency within the U.S. Department of Defense. The $11,710.65 firm fixed-price delivery order was awarded to AmerisourceBergen Drug Corporation, a major pharmaceutical distribution company. The contract has a period of performance through November 2024 and is not designated as a set-aside. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the...
This federal contract award is for the delivery of Dupixent 300 mg/2 ml pens to the Defense Logistics Agency (DLA), a defense agency. The $10,103.45 firm-fixed-price delivery order was awarded to AmerisourceBergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract has an ultimate completion date of April 29, 2024 and was awarded on April 26, 2024. This delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the...
This federal contract award is for the delivery of Dupixent 300 mg/2 ml pen 2 ml, a specialty pharmaceutical product, to the Defense Logistics Agency (DLA). The $4,957.05 firm fixed-price delivery order was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, on December 18, 2023, with a completion date of December 19, 2023. The contract is not designated as a set-aside. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
  • SPE2DB20D3103
    Indefinite Delivery Contract
  • SPE2DB20D3103-SPE2DB23FN7V3
    Delivery Order

This federal contract award is for the delivery of Dupixent 300 mg/2 ml pen (2 ml) to the Defense Logistics Agency (DLA). The $64,505.40 Firm Fixed Price delivery order was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, on June 22, 2023, with a completion date of June 23, 2023. The contract is not designated as a set-aside. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical through November 2026, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally.

Generated 2/27/25, 11:56 AM